Cardiff Oncology Inc. sell dimontalban
Start price
10.06.22
/
70%
€1.77
Target price
10.06.23
€0.20
Performance (%)
24.58%
End price
26.06.22
€2.20
Summary
This prediction ended on 26.06.22 with a price of €2.20. The SELL prediction by dimontalban finished with a performance of 24.58%. dimontalban has 70% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Cardiff Oncology Inc. | -9.273% | -9.273% | 69.267% |
| iShares Core DAX® | -1.189% | -3.063% | 10.586% |
| iShares Nasdaq 100 | 3.663% | 8.732% | 34.914% |
| iShares Nikkei 225® | -1.422% | -0.414% | 3.883% |
| iShares S&P 500 | 2.182% | 4.907% | 28.279% |
According to dimontalban what are the pros and cons of Cardiff Oncology Inc. for the foreseeable future?
Pros
Valuable balance sheet
Capable Management
Innovative
Future proof or reliable business model
Fair valuation
Very good company culture
Some uniques
Differentiated customer and product portfolio
Sustainability is important
Top 10 in its market
Known brand
Cons
Probably not worthwhile Investment
very negative Cash Flow expected
Junk rating
Increased challenges to pay loans and raise capital
high free float
Revenue decline/stagnation expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
Very low/no dividend yield expected
Little Investments for future growth
ROE lower than 5% per year
Growths slower than the competition
High risks for its business
Very high cyclical dependencies
Comments by dimontalban for this prediction
In the thread Trovagene diskutieren
Kursziel geändert auf 0,0
Kursziel geändert auf 0,2